| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Departments of Surgery [A. E. C., J. R. W., J. D. G., J. J. M.], Internal Medicine [B. G. R., J. J. M.], and Biostatistics [T. M. B.], University of Michigan, Ann Arbor, Michigan 48109-0932; Department of Medicine, Stanford University, Stanford, California 94305 [P. P. L.]; and Department of Pathology, Loyola University, Maywood, Illinois 60153 [B. J. N.]
Purpose: The objectives of this study were to assess the toxicity and immunologicalresponse induced by the intradermal (i.d) administration of tumor lysate-pulsed dendritic cells (DCs).
Experimental Design: Patients with stage IV solid malignancies were treated in cohorts that received 106, 107, and 108 DCs i.d. every 2 weeks for three vaccines. Each vaccine was composed of a mixture of half DCs pulsed with autologous tumor lysate and the other half with keyhole limpet hemocyanin (KLH). Peripheral blood mononuclear cells (PBMCs) harvested 1 month after the last immunization was compared with pretreatment PBMCs for immunological response. Delayed-type hypersensitivity reactivity to tumor antigen and KLH was also assessed.
Results: Fourteen patients received all three vaccines and were evaluable for toxicity and/or immunological monitoring. There were no grade 3 or 4 toxicities associated with the vaccines or major evidence of autoimmunity. Local accumulation of CD4+ and CD8+ T cells were found at the vaccination sites. There was a significant proliferative response of PBMCs to KLH induced by the vaccine. In 5 of 6 patients, the vaccine resulted in increased IFN-
production by PBMCs to KLH in an ELISPOT assay. Using the same assay, 3 of 7 patients’ PBMCs displayed increased IFN- production in response to autologous tumor lysate. One patient with melanoma also was observed to have an increased frequency of MART-1- and gp100-reactive CD8+ T cells after vaccination. By delayed-type hypersensitivity testing, 8 of 9 and 4 of 10 patients demonstrated reactivity to KLH and autologous tumor, respectively. Two patients with melanoma experienced a partial and a minor response, respectively.
Conclusion: The administration of tumor lysate-pulsed DCs is nontoxic and capable of inducing immunological response to tumor antigen. Additional studies are necessary to improve tumor rejection responses.
This article has been cited by other articles:
|
|
 |
|
  B. Vasir, Z. Wu, K. Crawford, J. Rosenblatt, C. Zarwan, A. Bissonnette, D. Kufe, and D. Avigan Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells J. Immunol., July 1, 2008; 181(1): 808 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lizee, M. A. Cantu, and P. Hwu Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy Clin. Cancer Res., September 15, 2007; 13(18): 5250 - 5255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Grolleau-Julius, M. R. Garg, R. Mo, L. L. Stoolman, and R. L. Yung Effect of Aging on Bone Marrow-Derived Murine CD11c+CD4-CD8{alpha}- Dendritic Cell Function. J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2006; 61(10): 1039 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms. Clin. Cancer Res., August 15, 2006; 12(16): 4794 - 4803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Iinuma, K. Okinaga, R. Fukushima, T. Inaba, K. Iwasaki, A. Okinaga, I. Takahashi, and M. Kaneko Superior Protective and Therapeutic Effects of IL-12 and IL-18 Gene-Transduced Dendritic Neuroblastoma Fusion Cells on Liver Metastasis of Murine Neuroblastoma J. Immunol., March 15, 2006; 176(6): 3461 - 3469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Moran, M. Collier, K. P. McKinnon, N. L. Davis, R. E. Johnston, and J. S. Serody A Novel Viral System for Generating Antigen-Specific T Cells J. Immunol., September 1, 2005; 175(5): 3431 - 3438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tokunaga, T. Murakami, Y. Endo, M. Nishizaki, S. Kagawa, N. Tanaka, and T. Fujiwara Human Monocyte-Derived Dendritic Cells Pulsed with Wild-Type p53 Protein Efficiently Induce CTLs against p53 Overexpressing Human Cancer Cells Clin. Cancer Res., February 1, 2005; 11(3): 1312 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Lee, H. Torisu-Itakara, A. J. Cochran, A. Kadison, Y. Huynh, D. L. Morton, and R. Essner Quantitative Analysis of Melanoma-Induced Cytokine-Mediated Immunosuppression in Melanoma Sentinel Nodes Clin. Cancer Res., January 1, 2005; 11(1): 107 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ito, Q. Li, A. B. Shreiner, R. Okuyama, M. N. Jure-Kunkel, S. Teitz-Tennenbaum, and A. E. Chang Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines Cancer Res., November 15, 2004; 64(22): 8411 - 8419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Avigan Dendritic Cell-Tumor Fusion Vaccines for Renal Cell Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6347S - 6352S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wong, R. Lau, J. Chang, T. Kuus-Reichel, V. Brichard, C. Bruck, and J. Weber Immune Responses to a Class II Helper Peptide Epitope in Patients with Stage III/IV Resected Melanoma Clin. Cancer Res., August 1, 2004; 10(15): 5004 - 5013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nencioni and P. Brossart Cellular Immunotherapy with Dendritic Cells in Cancer: Current Status Stem Cells, July 1, 2004; 22(4): 501 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Stift, M. Sachet, R. Yagubian, C. Bittermann, P. Dubsky, C. Brostjan, R. Pfragner, B. Niederle, R. Jakesz, M. Gnant, et al. Dendritic Cell Vaccination in Medullary Thyroid Carcinoma Clin. Cancer Res., May 1, 2004; 10(9): 2944 - 2953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Skitzki, R. A. Craig, R. Okuyama, R. N. Knibbs, K. McDonagh, A. E. Chang, and L. M. Stoolman Donor Cell Cycling, Trafficking, and Accumulation during Adoptive Immunotherapy for Murine Lung Metastases Cancer Res., March 15, 2004; 64(6): 2183 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Berd, T. Sato, H. C. Maguire Jr, J. Kairys, and M. J. Mastrangelo Immunopharmacologic Analysis of an Autologous, Hapten-Modified Human Melanoma Vaccine J. Clin. Oncol., February 1, 2004; 22(3): 403 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Teitz-Tennenbaum, Q. Li, S. Rynkiewicz, F. Ito, M. A. Davis, C. J. Mcginn, and A. E. Chang Radiotherapy Potentiates the Therapeutic Efficacy of Intratumoral Dendritic Cell Administration Cancer Res., December 1, 2003; 63(23): 8466 - 8475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Teramoto, K. Kontani, Y. Ozaki, S. Sawai, N. Tezuka, T. Nagata, S. Fujino, Y. Itoh, O. Taguchi, Y. Koide, et al. Deoxyribonucleic Acid (DNA) Encoding a Pan-Major Histocompatibility Complex Class II Peptide Analogue Augmented Antigen-specific Cellular Immunity and Suppressive Effects on Tumor Growth Elicited by DNA Vaccine Immunotherapy Cancer Res., November 15, 2003; 63(22): 7920 - 7925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. D. Humes Cell Therapy: Leveraging Nature's Therapeutic Potential J. Am. Soc. Nephrol., August 1, 2003; 14(8): 2211 - 2213. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Santini and F. Belardelli Advances in the Use of Dendritic Cells and New Adjuvants for the Development of Therapeutic Vaccines Stem Cells, July 1, 2003; 21(4): 495 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Parmiani, L. Pilla, C. Castelli, and L. Rivoltini Vaccination of patients with solid tumours Ann. Onc., June 1, 2003; 14(6): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takeuchi, C. Kuo, D. L. Morton, H.-J. Wang, and D. S. B. Hoon Expression of Differentiation Melanoma-associated Antigen Genes Is Associated with Favorable Disease Outcome in Advanced-Stage Melanomas Cancer Res., January 15, 2003; 63(2): 441 - 448. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
